SCHEMBL379692

SCHEMBL379692

Fc1ccccc1-c1nnc2cc(Cl)ccn12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.52
KDM4E B2RXH2 2/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PDE2A O00408 3/20 0.45
PDE10A Q9Y233 3/20 0.45
MAPK13 O15264 2/20 0.41
ABL1 P00519 1/20 0.40
PDGFRA P16234 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CDK7 P50613 1/20 0.40
BTK Q06187 1/20 0.40
MAP4K2 Q12851 1/20 0.40
AURKB Q96GD4 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
HPRT1 P00492 1/20 0.40
KCNN4 O15554 1/20 0.36
POLB P06746 1/20 0.36
DCTPP1 Q9H773 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379822 0.84 HSD11B1 (0.50) HSD11B1KDM4EKMT2AHSD17B10PDE2A
SCHEMBL10288930 0.83 DNMT1 (0.49) HSD11B1KDM4EHSD17B10PDE2APDE10A
SCHEMBL10288933 0.83 KDM4E (0.46) HSD11B1KDM4EKMT2AHSD17B10PDE2A
SCHEMBL380073 0.82 HSD11B1 (0.40) HSD11B1KDM4EKMT2APDE2APDE10A
SCHEMBL3621998 0.82 HSD11B1 (0.40) HSD11B1KDM4EPDE2APDE10AMAPK13
SCHEMBL2023855 0.74 PDE2A (0.47) HSD11B1KDM4EKMT2APDE2APDE10A
SCHEMBL13385743 0.71 HSD11B1 (0.53) HSD11B1KDM4EPDE2APDE10AMAPK13
SCHEMBL3623290 0.70 HSD11B1 (0.47) HSD11B1KDM4EKMT2AHSD17B10PDE2A
SCHEMBL10288932 0.70 HSD11B1 (0.47) HSD11B1KDM4EKMT2AHSD17B10MAPK13
SCHEMBL379749 0.70 HSD11B1 (0.48) HSD11B1KDM4EKMT2AHSD17B10PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086973-B1 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC (US) 2012-01-25 EP disclosed
EP-2086973-B1 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC (US) 2012-01-25 EP disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
EP-2086973-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF Amgen Inc., (US) 2009-08-12 EP disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof MAPK1, MAP3K1, MAP3K7 HSD11B1 2370/4885KDM4E 2389/4885KMT2A 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.